Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

9-Valent human papillomavirus vaccine: a review of the clinical development program
Alain Luxembourg, Erin Moeller
Expert Review of Vaccines (2017) Vol. 16, Iss. 11, pp. 1119-1139
Closed Access | Times Cited: 54

Showing 1-25 of 54 citing articles:

Final analysis of a 14-year long-term follow-up study of the effectiveness and immunogenicity of the quadrivalent human papillomavirus vaccine in women from four nordic countries
Susanne K. Kjær, Mari Nygård, Karin Sundström, et al.
EClinicalMedicine (2020) Vol. 23, pp. 100401-100401
Open Access | Times Cited: 144
Advances in Infectious Disease Vaccine Adjuvants
Jingyi Fan, Shengbin Jin, Lachlan Gilmartin, et al.
Vaccines (2022) Vol. 10, Iss. 7, pp. 1120-1120
Open Access | Times Cited: 76
Nine-valent HPV vaccine efficacy against related diseases and definitive therapy: comparison with historic placebo population
Anna R. Giuliano, Elmar A. Joura, Suzanne M. Garland, et al.
Gynecologic Oncology (2019) Vol. 154, Iss. 1, pp. 110-117
Open Access | Times Cited: 80
Prophylactic HPV vaccines in patients with HPV-associated diseases and cancer
Miriam Reuschenbach, John Doorbar, Marta del Pino, et al.
Vaccine (2023) Vol. 41, Iss. 42, pp. 6194-6205
Open Access | Times Cited: 35
Immunogenicity of the 9-valent human papillomavirus vaccine: Post hoc analysis from five phase 3 studies
Anna R. Giuliano, Joel M. Palefsky, Stephen E. Goldstone, et al.
Human Vaccines & Immunotherapeutics (2025) Vol. 21, Iss. 1
Open Access | Times Cited: 1
Stability study of recombinant 9-valent human papillomavirus vaccine based on Escherichia coli expression system
Yuying Liu, Dan Chen, Li Zhao, et al.
Human Vaccines & Immunotherapeutics (2025) Vol. 21, Iss. 1
Open Access | Times Cited: 1
Systematic literature review of cross-protective effect of HPV vaccines based on data from randomized clinical trials and real-world evidence
Darron R. Brown, Elmar A. Joura, Glorian Yen, et al.
Vaccine (2021) Vol. 39, Iss. 16, pp. 2224-2236
Closed Access | Times Cited: 45
Ten-Year Follow-up of 9-Valent Human Papillomavirus Vaccine: Immunogenicity, Effectiveness, and Safety
Jaime Restrepo, Teobaldo Herrera, Rudiwilai Samakoses, et al.
PEDIATRICS (2023) Vol. 152, Iss. 4
Closed Access | Times Cited: 23
Epstein–Barr Virus and Human Papillomaviruses Interactions and Their Roles in the Initiation of Epithelial–Mesenchymal Transition and Cancer Progression
Farhan Cyprian, Halema F. Al-Farsi, Semir Vranić, et al.
Frontiers in Oncology (2018) Vol. 8
Open Access | Times Cited: 54
Human papillomavirus vaccine disease impact beyond expectations
Sílvia de Sanjosé, María Brotons, D. Scott LaMontagne, et al.
Current Opinion in Virology (2019) Vol. 39, pp. 16-22
Closed Access | Times Cited: 45
Long-term effectiveness of the nine-valent human papillomavirus vaccine in Scandinavian women: interim analysis after 8 years of follow-up
Susanne K. Kjær, Mari Nygård, Karin Sundström, et al.
Human Vaccines & Immunotherapeutics (2020) Vol. 17, Iss. 4, pp. 943-949
Open Access | Times Cited: 44
Immunogenicity and safety of a nine-valent human papillomavirus vaccine in women 27–45 years of age compared to women 16–26 years of age: An open-label phase 3 study
Elmar A. Joura, Àngels Ulied, Corinne Vandermeulen, et al.
Vaccine (2021) Vol. 39, Iss. 20, pp. 2800-2809
Open Access | Times Cited: 33
THE ROLE OF TRANSFORMING GROWTH FACTOR Β IN CERVICAL CARCINOGENESIS
Kleber Paiva Trugilo, Guilherme Cesar Martelossi Cebinelli, Eliza Pizarro Castilha, et al.
Cytokine & Growth Factor Reviews (2024)
Closed Access | Times Cited: 6
Prevalence, incidence, and natural history of HPV infection in adult women ages 24 to 45 participating in a vaccine trial
Daron G. Ferris, Darron R. Brown, Anna R. Giuliano, et al.
Papillomavirus Research (2020) Vol. 10, pp. 100202-100202
Open Access | Times Cited: 39
Portrayals of 2v, 4v and 9vHPV vaccines on Chinese social media: a content analysis of hot posts on Sina Weibo
Fangzhou Zhou, Wen Zhang, Hongning Cai, et al.
Human Vaccines & Immunotherapeutics (2021) Vol. 17, Iss. 11, pp. 4433-4441
Open Access | Times Cited: 24
Design of a phase III efficacy, immunogenicity, and safety study of 9-valent human papillomavirus vaccine in prevention of oral persistent infection in men
Anna R. Giuliano, Timothy Wilkin, Oliver Bautista, et al.
Contemporary Clinical Trials (2021) Vol. 115, pp. 106592-106592
Closed Access | Times Cited: 24
Orogenital Human Papillomavirus Infection and Vaccines: A Survey of High- and Low-Risk Genotypes Not Included in Vaccines
Michela Buttà, Nicola Serra, Vera Panzarella, et al.
Vaccines (2023) Vol. 11, Iss. 9, pp. 1466-1466
Open Access | Times Cited: 10
Human Papillomavirus Infection in Partners of Women Attending Cervical Cancer Screening: A Pilot Study on Prevalence, Distribution, and Potential Use of Vaccines
Arianna Sucato, Nicola Serra, Michela Buttà, et al.
Vaccines (2025) Vol. 13, Iss. 2, pp. 172-172
Open Access
Human Papillomaviruses: An Ancient Enemy
Van G. Wilson
(2025), pp. 293-321
Closed Access
HPV awareness and vaccine knowledge gaps among adults in bahrain: a community-based study
Reem Alzahrani, Maha Al‐Ghamdi, AKM Firoj Mahmud, et al.
Deleted Journal (2025) Vol. 22, Iss. 1
Open Access
Co-Incidence of Epstein–Barr Virus and High-Risk Human Papillomaviruses in Cervical Cancer of Syrian Women
Hamda Al-Thawadi, Lina Ghabreau, Tahar Aboulkassim, et al.
Frontiers in Oncology (2018) Vol. 8
Open Access | Times Cited: 32
Development of identity assay for human papillomavirus genotypes using simple Plex microfluidic automated ELISA
Katherine Esposito, Richard R. Rustandi, Matthew Schombs
Vaccine X (2025), pp. 100621-100621
Open Access
Human papillomavirus vaccination update: Nonavalent vaccine and the two-dose schedule
Julia Brotherton
Australian Journal of General Practice (2018) Vol. 47, Iss. 7, pp. 417-421
Open Access | Times Cited: 21
Co-incidence of Human Papillomaviruses and Epstein–Barr Virus Is Associated With High to Intermediate Tumor Grade in Human Head and Neck Cancer in Syria
Ishita Gupta, Lina Ghabreau, Hamda Al-Thawadi, et al.
Frontiers in Oncology (2020) Vol. 10
Open Access | Times Cited: 20
Three-Year Follow-up of 2-Dose Versus 3-Dose HPV Vaccine
Jacob Bornstein, Surita Roux, Lone Kjeld Petersen, et al.
PEDIATRICS (2020) Vol. 147, Iss. 1
Open Access | Times Cited: 20
Page 1 - Next Page

Scroll to top